A bit more reading on AAV vectors. Just as "oils aint oils" not every AAV8 (or 5 or 2 etc) is the same AAV8. Uniqure's AAV5 likewise may be specifically engineered to have characteristics very useful for Hep B. Indeed, as the first gene therapy company to get to the market, their specific AAV5 has a strong pedigree.
From http://www.nature.com/srep/2013/130513/srep01832/full/srep01832.html
"We have recently developed novel AAV2 and AAV8 vectors by targeted modification of capsid phosphodegrons which circumvents the host-cellular serine/threonine kinase phosphorylation and ubiquitination of the viral capsid16, 18. These modifications improved the hepatic gene expression of AAV2 and AAV8 vectors by up to 14 and 46-fold, respectively. Since a majority of these residues are conserved in the VP1-3 capsid region of both AAV1 and AAV5 vectors and in anticipation of improving their transduction efficiency, we performed targeted mutagenesis in AAV1 and AAV5 vectors and evaluated them in vitro and in vivo."
This field is very complex, to say the least!
BLT Price at posting:
$1.59 Sentiment: LT Buy Disclosure: Held
